Clinical trials: Hematological Neoplasm
Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
This phase I trial studies the side effects and best dose of rivogenlecleucel, and how well it works, in treating patients with blood cancer that has come back (recurrent) after stem cell transplant.
- Conditions
- Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm
- Trial name
- NCT03807063
- Testing
- Rivogenlecleucel, Rimiducid
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Solid Tumors
Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors
Study of ABT-869 in Combination with Tarceva in Subjects with Solid Tumors
- Trial name
- NCT00754104
- Testing
- ABT-869, Tarceva
- Sponsor
- Abbott
Malignancy, Cancer
Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
This is a prospective interventional study designed to investigate the effect of Immune Reconstitution clinic visits and pneumococcal vaccination (PCV-21) on infection risk, anti-infective prophylaxis adherence, and vaccine…
- Conditions
- Malignancy, Cancer, Hematological Malignancies, Lymphoma
- Trial name
- NCT07071909
- Testing
- Commercial CAR-T, Investigational CAR-T
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hematologic Malignancies
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
- Trial name
- NCT01476657
- Testing
- IPI-145 (duvelisib)
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- SecuraBio
Neoplasms
Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials
This screening study is intended to determine preliminary eligibility of participants who may be potential candidates for GlaxoSmithKline's Adoptive T-cell therapy studies by screening for appropriate biomarkers.
- Trial name
- NCT05100316
- Testing
- Screening Platform
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Polycythemia Vera (PV)
Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
This trial adopts an open, randomized, parallel controlled, multicenter clinical trial design planning to enroll patients with polycythemia vera who are resistant/intolerant to hydroxyurea or interferon.
- Trial name
- NCT07232290
- Testing
- Flonoltinib 75mg, Flonoltinib 100mg, Flonoltinib 125mg
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Hematological Malignancies
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
This is a Phase 1, multicenter, open-label clinical study of HMPL-506 administered orally in the treatment of hematological malignancies.
- Trial name
- NCT06387082
- Testing
- HMPL-506
- Where
- 16 sites in China
- Volunteers
- 132 people
- Sponsor
- Hutchmed
Chemotherapy-induced Thrombocytopenia
Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung…
- Trial name
- NCT03471078
- Testing
- Avatrombopag
- Where
- 55 sites in United States, China and 5 more
- Volunteers
- 122 people
- Sponsor
- Sobi, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00008125
- Testing
- filgrastim, carboplatin, docetaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pittsburgh
Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia
Improving Blood Stem Cell Collection and Transplant Procedures
Background: People who have some kinds of cancer can benefit from donated bone marrow stem cells. These stem cells help produce healthy bone marrow and slow or stop the spread of abnormal cells.
- Conditions
- Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, CML (Chronic Myelogenous Leukemia
- Trial name
- NCT01517035
- Testing
- Stem Cell Transplantation
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Relapse of Hematological Malignancies
Secondary Haplo HSCT for Relapse After Initial Allogeneic HSCT
Relapse of underlying hematologic malignancies after allogeneic hematopoietic stem cell transplantation (HSCT) is frequently treated by a second allogeneic HSCT (HSCT2).
- Trial name
- NCT01997918
- Volunteers
- 60 people
- Sponsor
- University Hospital Tuebingen
Hematopoietic Malignancies, Haploidentical Hematopoietic Stem Cell Transplantation
Cousin vs. Sibling Donors in Haplo-HSCT
This observational study aims to emulate a hypothetical pragmatic, multicenter, non-blinded clinical trial enrolling adult patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with grafts…
- Conditions
- Hematopoietic Malignancies, Haploidentical Hematopoietic Stem Cell Transplantation, Donor
- Trial name
- NCT07662382
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Cancer and / or Hematological Malignancy, Hematopoetic Stem Cell Transplantation
Virtual Reality Intervention for Symptom Management in Stem Cell Transplantation
The goal of this clinical trial is to evaluate whether a virtual reality (VR) intervention based on the Symptom Management Model can reduce physical and psychosocial symptoms during hematopoietic stem cell transplantation (HSCT)…
- Conditions
- Cancer and / or Hematological Malignancy, Hematopoetic Stem Cell Transplantation, Nursing Interventions, Symptom Management
- Trial name
- NCT07145359
- Testing
- Virtual Reality Intervention
- Volunteers
- 30 people
- Sponsor
- Halic University
Isocitrate Dehydrogenase Gene Mutation
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant hematological malignancies that harbor IDH…
- Trial name
- NCT04764474
- Testing
- HMPL-306
- Where
- 15 sites in United States, Spain
- Volunteers
- 46 people
- Sponsor
- Hutchmed
Hematologic Cancer
Research-Action in Hematology From Hospitalization to Home
Objective : To study and support the hospitalization and the return home of patients with the help of a psychological follow-up started in a hospital institution and which will continue in the patient's home, based on the…
- Trial name
- RAH HD (NCT06053918)
- Testing
- additional follow-up extension at home
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Caen
Solid Tumor Malignancy, Hematologic Malignancy
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
Background: Coronavirus disease (COVID-19) is a viral infection. It has spread rapidly across the globe. It has overwhelmed health systems.
- Conditions
- Solid Tumor Malignancy, Hematologic Malignancy, Leukemia, Lymphoma
- Trial name
- NCT04847050
- Testing
- Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood…
- Trial name
- Aquarius (NCT07154823)
- Testing
- None - Observational Study
- Where
- 13 sites in United States
- Volunteers
- 550 people
- Sponsor
- Tempus AI
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
This phase I trial is studying the side effects and best dose of bortezomib when given together with fludarabine with or without rituximab in treating patients with relapsed or refractory indolent non-Hodgkin's lymphoma or…
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Trial name
- NCT00068315
- Testing
- bortezomib, fludarabine phosphate, rituximab
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Hematological Malignancy
Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation
The goal of our study will be to determine the clinical and biological safety of infusing immuno-selected NK (Natural Killer) CD3-/CD56+ cells, early after allogeneic transplantation with colony stimulating factor (G-CSF)…
- Trial name
- DLI-NK (NCT01853358)
- Testing
- NK Cell infusion
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Institut Paoli-Calmettes
Hematologic Neoplasms
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
The purpose of this study is to determine the safety and to establish the recommended phase 2 dose (RP2D) for the combination of ibrutinib and nivolumab in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic…
- Trial name
- NCT02329847
- Testing
- Ibrutinib, Nivolumab
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 144 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.